Immune Checkpoint Inhibitors for the Therapy of Thymoma
JTO Clin Res Rep
.
2020 Feb 11;1(1):100011.
doi: 10.1016/j.jtocrr.2020.100011.
eCollection 2020 Mar.
Authors
Alicia Quilez
1
,
Edgar F Guillen
2
,
Luisa Sánchez
3
,
Jaime Espinós
3
,
Antonio González
3
,
Jesus Corral
3
Affiliations
1
Medical Oncology Department, University Hospital of Puerto Real, Cádiz, Spain.
2
Nuclear Medicine Department, Clínica Universidad de Navarra, Madrid, Spain.
3
Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
PMID:
34589913
PMCID:
PMC8474349
DOI:
10.1016/j.jtocrr.2020.100011
No abstract available
Keywords:
Complete response; No irAEs; Pembrolizumab; Thymoma.